Erste Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Erste Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.2M	Sell	76,558 -15,400	-17%	-$6.83M	0.3%	77
2026 Q1	$40.8M	Buy	91,958 +24,595	+37%	+$11.5M	0.38%	71
2025 Q4	$31M	Sell	67,363 -154	-0.2%	-$66.4K	0.26%	92
2025 Q3	$26.7M	Sell	67,517 -6,386	-9%	-$2.67M	0.26%	104
2025 Q2	$32.6M	Buy	73,903 +5,133	+7%	+$2.37M	0.27%	87
2025 Q1	$33.5M	Buy	68,770 +2,996	+5%	+$1.4M	0.43%	59
2024 Q4	$26.5M	Buy	65,774 +2,260	+4%	+$1.05M	0.33%	74
2024 Q3	$29.4M	Buy	63,514 +5,208	+9%	+$2.5M	0.35%	80
2024 Q2	$27.6M	Sell	58,306 -8,392	-13%	-$3.64M	0.36%	76
2024 Q1	$27.8M	Sell	66,698 -45,233	-40%	-$19.1M	0.38%	80
2023 Q4	$45.7M	Sell	111,931 -3,294	-3%	-$1.22M	0.67%	45
2023 Q3	$40.5M	Buy	115,225 +32,150	+39%	+$11.2M	0.7%	40
2023 Q2	$28.9M	Sell	83,075 -3,655	-4%	-$1.23M	0.51%	60
2023 Q1	$27.1M	Buy	86,730 +4,600	+6%	+$1.38M	0.52%	58
2022 Q4	$23.7M	Sell	82,130 -393	-0.5%	-$120K	0.5%	58
2022 Q3	$24.2M	Sell	82,523 -2,250	-3%	-$647K	0.54%	54
2022 Q2	$23.8M	Buy	84,773 +773	+0.9%	+$207K	0.53%	54
2022 Q1	$21.6M	Buy	84,000 +22,800	+37%	+$5.41M	0.41%	68
2021 Q4	$13.7M	Sell	61,200 -800	-1%	-$156K	0.25%	113
2021 Q3	$11.3M	Hold	62,000	–	–	0.22%	125
2021 Q2	$12.2M	Sell	62,000 -7,640	-11%	-$1.6M	0.24%	116
2021 Q1	$14.8M	Hold	69,640	–	–	0.36%	83
2020 Q4	$16.3M	Buy	69,640 +7,738	+13%	+$1.78M	0.45%	68
2020 Q3	$16.7M	Sell	61,902 -6,748	-10%	-$1.86M	0.57%	53
2020 Q2	$19.6M	Sell	68,650 -22,750	-25%	-$6.17M	0.78%	35
2020 Q1	$21.2M	Buy	91,400 +9,500	+12%	+$2.18M	1.23%	16
2019 Q4	$18.1M	Sell	81,900 -130,000	-61%	-$26.3M	0.8%	29
2019 Q3	$35.7M	Sell	211,900 -9,100	-4%	-$1.61M	1.9%	4
2019 Q2	$40.1M	Buy	221,000 +18,300	+9%	+$3.2M	2.13%	4
2019 Q1	$37.2M	Sell	202,700 -16,000	-7%	-$2.96M	2.08%	6
2018 Q4	$35.4M	Buy	+218,700	New	+$37.9M	2.38%	4

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Erste Asset Management's VRTX Position: Q2 2026 in Review

Erste Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, selling an estimated $6.83M and leaving 76,558 shares worth $38.2M. The position accounts for 0.3% of the portfolio, ranked #77.

Erste Asset Management first reported a position in VRTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $45.7M in Q4 2023. 670 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Erste Asset Management held 76,558 shares of Vertex Pharmaceuticals worth $38.2M as of Q2 2026.
Erste Asset Management sold 15,400 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.83M.
Vertex Pharmaceuticals made up 0.3% of Erste Asset Management's portfolio in Q2 2026, its #77 holding.
Erste Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
Erste Asset Management's Vertex Pharmaceuticals position peaked at $45.7M in Q4 2023.
670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.